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OBJECTIVE: To assess quality of life and quality of life changes
in subjects with major depression treated pharmacologically 
with S-adenosyl-methyonine vs. imipramine. METHODS: This
quality of life assessment was a part of the MC4 trial, a short-
term, multicentre, prospective, randomised, double blind, double
placebo controlled study of the anti-depressant effect of 28 days
course of intramuscular SAMe 400mg per day vs. oral
imipramine 150mg per day in subjects during a major depres-
sion episode. We used the EuroQol instrument to evaluate QoL
before (t0) and after treatment (day 28). RESULTS: The analy-
sis considered 257 patients during a major depressive episode
that completed the study (63% female; mean age 49 + 13 years).
Subjects had extremely low comparable levels of overall QoL as
measured through the EQ-VAS (33.7 + 14 on average), which
increased comparably as an effect of treatment with both SAMe
and imipramine (63.1 + 20). Several domains of QoL which
where impaired before treatment, improved afterwards, mainly
anxiety and depression, and ability to perform usual activities.
EQ-VAS was only fairly correlated with physician-administered
depression scales at the start of treatment, while the correlation
was very good at the end of treatment. Self administered depres-
sion scales showed a similar behavior as the EuroQol. CON-
CLUSION: Our estimates show that the level of perceived
overall QoL in subjects with a major depressive episode is dra-
matically low. Pharmacological treatment with intramuscular
SAMe or oral imipramine has a similar, noticeable, positive
impact on QoL.
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OBJECTIVES: Depression is a prevalent and debilitating disor-
der, often undiagnosed. Patients may present with a broad range
of symptoms including mood, somatic and painful symptoms.
Our aim was to create a comprehensive symptom checklist to
guide questionnaire development for the diagnosis and outcomes
assessment of depression. METHODS: A systematic literature
review was conducted to list all emotional, somatic and painful
physical symptoms from validated scales in depression. One
hundred ﬁfty semi-structured interviews were conducted with 50
clinicians, 50 patients with diagnosed depression (DEP) and 50
patients with physical symptoms of depression, referred to by
physicians as masked depression (MD) and Somatoform disor-
ders, in France, Germany, Italy, Spain and the UK. The clinicians
were asked to describe their patients’ symptoms, the proﬁles of
DEP and MD patients, and to comment and rate the listed symp-
toms for DEP and MD patients. The patients were asked to
describe their symptoms, to comment and rate the listed symp-
toms. RESULTS: Twenty-two validated scales covering symp-
toms of depression were reviewed. Two lists of symptoms were
created: one including medical terms for clinician interviews, and
one including lay terms for patient interviews. Although clini-
cian interviews tend to show differences between DEP and MD
patients, the majority of symptoms were reported to exist in both
groups. Moreover, patients’ reports showed fewer differences
between DEP and MD than clinicians’ reports. Overall, the
results were comparable between countries. The ﬁnal checklist
covers nine emotional symptoms and 37 somatic symptoms in
nine groups (gastrointestinal, cardiopulmonary, neurological,
neuropsychological, neuromuscular, urogenital, pain, sleep,
autonomic system). CONCLUSIONS: The checklist is the ﬁrst
comprehensive description of symptoms of depression, including
emotional, somatic and painful physical symptoms. This check-
list will guide further instrument development for the diagnosis
and outcomes assessment of depressed patients.
RESPIRATORY DISEASES
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OBJECTIVE: The MOSAIC study compared the effectiveness of
moxiﬂoxacin to a basket of 3 standard antibiotic regimens in
730 patients with Anthonisen 1 acute exacerbations of chronic
bronchitis (AECB). The clinical outcomes were assessed 7–10
days after study treatment, and then every month until a new
AECB or up to 9 months. The study showed superiority of mox-
iﬂoxacin on clinical cure (return to pre-AECB status) and equiv-
alence to the comparator arm on clinical success (cure or
improvement). The long-term beneﬁt of moxiﬂoxacin (compos-
ite endpoint) was statistically signiﬁcant up to 5 months but not
at 9 months. METHODS: Using the study data set, exploratory
post-hoc logistic regression analyses were performed to identify
prognostic factors of short and long term clinical outcomes, and
their potential role in confounding the results of the trial.
RESULTS: Clinical cure was positively inﬂuenced by treatment
with moxiﬂoxacin (OR = 1.485) at all levels of the identiﬁed risk
factors, i.e. cardiopulmonary disease (OR = 0.58), FEV1 (OR =
0.48) and number of previous AECB (OR = 0.68). For clinical
success, the treatment with moxiﬂoxacin was signiﬁcantly supe-
rior to comparator (OR = 1.57) when adjusted on identiﬁed risk
factors, i.e. cardio-pulmonary disease (OR = 0.41) and use of
acute bronchodilatators (OR = 0.50). The long-term outcome
was positively affected by moxiﬂoxacin treatment up to 9
months (HR = 0.82) once adjusted on age (HR = 1.22), FEV1
(HR = 1.27), number of previous AECB (HR = 1.63), and acute
bronchodilator use (HR = 1.48). CONCLUSION: This post-hoc
analysis indicates that even in a double-blinded, a priori strati-
ﬁed trial conducted in a clinically homogeneous population,
between-group differences could still be confounded by under-
lying prognosis factors, leading to an underestimation of the
treatment impact. Future outcome trials and observational
studies in chronic bronchitis should take the identiﬁed risk
factors into account, either by using a stratiﬁed randomisation
scheme or by adjusting the statistical analysis plan in a pre-
speciﬁed manner.
